Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 6 results.
User Information
Export Records
  1. 1.   Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
  2. Cecchini, Michael; Pilat, Mary Jo; Uboha, Nataliya; Azad, Nilofer S; Cho, May; Davis, Elizabeth J; Ahnert, Jordi Rodon; Tinoco, Gabriel; Shapiro, Geoffrey I; Khagi, Simon; Powers, Benjamin; Spencer, Kristen; Groisberg, Roman; Drappatz, Jan; Chen, Li; Das,Bishu; Bao, Xun; Li, Jing; Narayan, Azeet; Vu, Dennis; Patel, Abhijit; Niger, Monica; Doroshow, Deborah; Durecki, Diane; Boerner, Scott A; Bindra, Ranjit; Ivy, Percy; Shyr, Derek; Shyr, Yu; LoRusso, Patricia M
  3. Cancer. 2025, Feb 15; 131(4): e35755.
  1. 2.   Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
  2. Glade Bender, Julia L; Pinkney, Kerice; Williams,Mickey; Roy-Chowdhuri, Sinchita; Patton, David R; Coffey, Brent D; Reid, Joel M; Piao, Jin; Saguilig, Lauren; Alonzo, Todd A; Berg, Stacey L; Ramirez, Nilsa C; Fox, Elizabeth; Weigel, Brenda J; Hawkins, Douglas S; Mooney, Margaret M; Takebe, Naoko; Tricoli, James V; Janeway, Katherine A; Seibel, Nita L; Parsons, Donald W
  3. The Oncologist. 2024, May 30;
  1. 3.   A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib
  2. Yamamoto, Jun; Murata, Takuya; Tashiro, Yoshihiko; Higuchi, Takashi; Sugisawa, Norihiko; Nishino, Hiroto; Inubushi, Sachiko; Sun, Y U; Lim, Hyein; Miyake, Kentaro; Hongo, Atsushi; Nomura, Tsunehisa; Saitoh, Wataru; Moriya, Takuya; Tanino, Hirokazu; Hozumi, Chihiro; Bouvet, Michael; Singh,Shree Ram; Endo, Itaru; Hoffman, Robert M
  3. Anticancer research. 2020, May; 40(5): 2509-2514.
  1. 4.   Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11and low-MGMT expression
  2. Rathkey, Daniel; Khanal, Manakamana; Murai, Junko; Zhang, Jingli; Sengupta, Manjistha; Jiang, Qun; Morrow, Betsy; Evans,Christine; Chari,Raj; Fetsch, Patricia; Chung, Hye-Jung; Xi, Liqiang; Roth, Mark; Filie, Armando; Raffeld, Mark; Thomas, Anish; Pommier, Yves; Hassan, Raffit
  3. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020, Jan 28; pii: S1556-0864(20)30035-6.
  1. 5.   Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
  2. Karzai, Fatima; VanderWeele, David; Madan, Ravi A; Owens, Helen; Cordes, Lisa M; Hankin, Amy; Couvillon, Anna; Nichols, Erin; Bilusic, Marijo; Beshiri, Michael L; Kelly, Kathleen; Krishnasamy, Venkatesh; Lee, Sunmin; Lee, Min-Jung; Yuno, Akira; Trepel, Jane B; Merino, Maria J; Dittamore, Ryan; Marté, Jennifer; Donahue, Renee N; Schlom, Jeffrey; Killian, Keith J; Meltzer, Paul S; Steinberg, Seth M; Gulley, James L; Lee, Jung-Min; Dahut, William L
  3. Journal for immunotherapy of cancer. 2018, Dec 04; 6(1): 141.
  1. 6.   Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
  2. Lee, Jung-Min; Hays, John L; Chiou, Victoria L; Annunziata, Christina M; Swisher, Elizabeth M; Harrell, Maria I; Yu, Minshu; Gordon, Nicolas; Sissung, Tristan M; Ji, Jay; Figg, William D; Minasian, Lori; Lipkowitz, Stanley; Wood, Bradford J; Doroshow, James; Kohn, Elise C
  3. Oncotarget. 2017, Oct 03; 8(45): 79175-79187.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel